Bessemer Group
VERV

Bessemer Group’s Verve Therapeutics VERV Stock Holding History

Bessemer Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-48
Closed -$1K – 2740
2025
Q2 		$1K Hold
48
– – ﹤0.01% 2366
2025
Q1 		$0 Buy
+48
New +$322 ﹤0.01% 2732

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bessemer Group's VERV Position: Q3 2025 in Review

Bessemer Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 48 shares — an estimated $1K sold.

Bessemer Group first reported a position in VERV in Q1 2025 and held it in 2 quarters. The position peaked at $1K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Bessemer Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 48 Verve Therapeutics shares in Q3 2025, an estimated $1K.
  • Bessemer Group first reported a position in Verve Therapeutics in Q1 2025 and held it in 2 quarters.
  • Bessemer Group's Verve Therapeutics position peaked at $1K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.